indatuximab ravtansine
mAbexperimentalADC
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2008 (NCT00723359)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Syndecan-1BINDING AGENT
SDC1 binding agent
- TubulinINHIBITOR
Tubulin inhibitor
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
- Syndecan-1INHIBITOR
SDC1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- Ravtansine
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109632 ↗
- ChEMBLCHEMBL1743031 ↗
Also known as
- bt062
- bt-062
- indatuximab ravtansine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01638936 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2012 | Biotest Pharmaceuticals, Harvard University |
| NCT01001442 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2010 | Biotest Pharmaceuticals, Harvard University |
| NCT00723359 | Phase 1 | Aug 1, 2008 | Biotest Pharmaceuticals, Harvard University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biotest Pharmaceuticals | For profit | 3 | 3 | 2 | 2008 |
| Harvard University | Academic/Hospital | 3 | 0 | 2 | 2008 |
2 organizations
Page 1 / 1